ARCALYST (rilonacept) is the first FDA-approved therapy for recurrent pericarditis
23 Marzo 2021
The FDA has approved ARCALYST ® (rilonacept), a weekly, subcutaneously-injected, recombinant fusion protein that blocks interleukin-1 alpha (IL-1α) and interleukin-1 beta (IL-1β) signaling, for the treatment of
